SLC5A2 and type 2 diabetes mellitus: In the patients with type 2 diabetes mellitus, ertugliflozin reduced the risk of first and total HFH and total HFH/CV death, further supporting the use of sodium-glucose cotransporter 2 inhibitors in the primary and secondary prevention of HFH [44].